Xeris Biopharma (XERS) Projected to Post Quarterly Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $57.61 million for the quarter.

Xeris Biopharma Stock Down 7.3 %

Shares of NASDAQ:XERS traded down $0.34 during midday trading on Tuesday, reaching $4.30. The company's stock had a trading volume of 2,749,279 shares, compared to its average volume of 1,909,571. The firm has a market cap of $672.46 million, a price-to-earnings ratio of -9.56 and a beta of 1.10. The business has a 50 day moving average price of $4.59 and a 200 day moving average price of $3.82. Xeris Biopharma has a 1 year low of $1.72 and a 1 year high of $6.07.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Jefferies Financial Group reiterated a "buy" rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Piper Sandler restated a "neutral" rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Craig Hallum boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $6.10.

Insider Buying and Selling at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 4.56% of the stock is owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.